Cerecor Inc. (NASDAQ:CERC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.
|
Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Financial Officer, and the Company entered into an amendment to the
employment agreement effective August 24, 2015. The amendment
provides that in the occurrence of a termination without cause (as
defined in Ms. Morris’ employment agreement), Ms. Morris will
receive continued payment of her base salary as in effect
immediately prior to the termination for one year following such
termination.
agreement is a summary, is not complete and is qualified in its
entirety by reference to the amendment, which will be filed as an
exhibit to the Companys Quarterly Report on Form 10-Q for the
period ended March 31, 2017.
Medical Officer, and the Company entered into an amendment to the
employment agreement effective May 5, 2015. The amendment provides
that in the occurrence of a termination without cause (as defined
in Dr. Marcus’ employment agreement), Dr. Marcus will receive
continued payment of his base salary as in effect immediately prior
to the termination for one year following such termination.
agreement is a summary, is not complete and is qualified in its
entirety by reference to the amendment, which will be filed as an
exhibit to the Companys Quarterly Report on Form 10-Q for the
period ended March 31, 2017.
|
|
|
|
About Cerecor Inc. (NASDAQ:CERC)
Cerecor, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment. The Company owns the rights to its COMTi platform. Catechol O methyltransferase (COMT) is an enzyme critical for the inactivation and metabolism of dopamine and its inhibition in the brain has applicability in treating subjects with neuropsychiatric conditions, including MDD, schizophrenia, Parkinson’s disease and pathological gambling. Its COMTi platform comprises COMT inhibitors with selectivity for membrane bound COMT, which is the dominant form of COMT. Cerecor Inc. (NASDAQ:CERC) Recent Trading Information
Cerecor Inc. (NASDAQ:CERC) closed its last trading session down -0.300 at 0.900 with 2,657,422 shares trading hands.